

TABLE 188: MORTALITY — ALL-CAUSE(S) AND LIVER-RELATED

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	MORTALITY ALL-CAUSE			MORTALITY LIVER-RELATED		
			n	N	%	n	N	%
Afdhal et al., 2014 ION-1	1	(6) SOF12 + LDV12	0	214	0%	NR		
		(7) SOF24 + LDV24	0	217	0%			
		(10) SOF12 + LDV12 + RBV12	0	217	0%			
		(11) SOF24 + LDV24 + RBV24	0	217	0%			
Buti et al., 2014 OPTIMIZE	1	(32) T12 PR24-48 RGT q8	1	371	0%	NR		
		T12 PR24-48 2b RGT q12	0	369	0%			
Fried et al., 2013 PILLAR	1	(1) PR48	0	77	0%	NR		
		(42) SIM12 PR24-48 RGT	0	77	0%			
Jacobson et al., 2011 ADVANCE	1	(1) PR48	1	361	0%	NR		
		(32) T12 PR24-48 RGT q8	2	363	1%			
Jacobson et al., 2014 QUEST-1	1	(1) PR48	0	130	0%	NR		
		(42) SIM12 PR24-48 RGT	0	264	0%			
Kumada et al., 2014	1b	(17) DCV24 + ASU24	0	135	0%	0	135	0%
Lawitz et al., 2013 NEUTRINO	1+4+5+6	(40) SOF12 + PR12	0	327	0%	0	327	0%
Lawitz et al., 2013 FISSION	2+3	(3) SOF12 + RBV12	2	263	1%	NR		
		(70) PR24	1	264	0%			
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	0	19	0%	0	19	0%
		(8) SOF8 + LDV8	0	20	0%	0	20	0%
		(9) SOF8 + LDV8 + RBV8	0	21	0%	0	21	0%
Lawitz et al., 2015-1 C-WORTHY	1	(57) GRZ12 + ELB12 (50 mg q.d.)	0	29	0%	NR		
		(59) GRZ18 + ELB18 (50 mg q.d.)	0	31	0%			
		(63) GRZ12 + ELB12 (50 mg q.d.) + RBV12	0	31	0%			
		(65) GRZ18 + ELB18 (50 mg q.d.) + RBV18	0	32	0%			
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	0	205	0%	0	205	0%
Manns et al., 2014 QUEST-2	1	(1) PR48	0	134	0%	NR		
		(42) SIM12 PR24-48 RGT	2	257	1%			
Marcellin et al., 2011	1	(32) T12 PR24-48 RGT q8	0	82	0%	NR		

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	MORTALITY ALL-CAUSE			MORTALITY LIVER-RELATED		
			n	N	%	n	N	%
		(33) T12 PR24-48 RGT q12	0	79	0%			
Mizokami et al. et al., 2015	1	(6) SOF12 + LDV12	0	83	0%	0	83	0%
		(10) SOF12 + LDV12 + RBV12	1	83	1%	0	83	0%
Molina et al., 2015-1+3+4 PHOTON-2	1+3+4	(4) SOF24 + RBV24	0	200	0%	0	200	0%
Molina et al., 2015-2 PHOTON-2	2	(3) SOF12 + RBV12	0	19	0%	0	19	0%
Nelson D. et al., 2015 ALLY-3	3	(19) DCV12 + SOF12	0	101	0%	NR		
Osinusi et al., 2013 SPARE-1	1	(4) SOF24 + RBV24	0	10	0%	0	10	0%
Osinusi et al., 2013 SPARE-2	1	(4) SOF24 + RBV24	0	25	0%	0	25	0%
		(71) SOF24 + RBV (low dose) 24	0	25	0%	0	25	0%
Osinusi et al., 2015	1	(6) SOF12 + LDV12	0	50	0%	0	50	0%
Poordad et al., 2011 SPRINT2	1	(1) PR48	4	176	2%	NR		
		(46) B24 PR28-48 RGT	2	257	1%			
Poordad et al. et al., 2015 UNITY-1	1	(26) DCV12 + ASU12 + BEC12	0	312	0%	NR		
Rodriguez-Torres et al., 2015	1+2+3+4	(40) SOF12 + PR12	0	23	0%	0	23	0%
Lawitz et al., 2015-1 C-WORTHY	1	(23) GRZ12 + ELB12 + RBV12	0	85	0%	0	85	0%
		(57) GRZ12 + ELB12 (50 mg q.d.)	0	44	0%	0	44	0%
		(61) GRZ8 + ELB8 (50 mg q.d.) + RBV8	0	30	0%	0	30	0%
Sulkowski et al., 2015-2 C-WORTHY	1	(57) GRZ12 + ELB12 (50 mg q.d.)	0	30	0%	0	30	0%
		(63) GRZ12 + ELB12 (50 mg q.d.) + RBV12	0	29	0%	0	29	0%
Sulkowski et al., 2014-1	2+3	(3) SOF12 + RBV12	0	26	0%	0	26	0%
Sulkowski et al., 2014-2	1	(4) SOF24 + RBV24	0	114	0%	0	114	0%
Sulkowski et al., 2014	1	(19) DCV12 + SOF12	0	41	0%	0	41	0%
Sulkowski et al., 2013-1	1	(1) PR48	0	6	0%	0	6	0%
		(39) T12 PR48 q8	0	7	0%	0	7	0%
Sulkowski et al., 2013-2	1	(1) PR48	0	8	0%	0	8	0%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	MORTALITY ALL-CAUSE			MORTALITY LIVER-RELATED		
			n	N	%	n	N	%
		(39) T12 PR48 q8	0	15	0%	0	15	0%
Zeuzem et al., 2015-1 C-EDGE	1+4+6	(22) GRZ12 + ELB12	2	288	1%	0	288	0%
Zeuzem et al., 2015-2 C-EDGE		(22) GRZ12 + ELB12	0	18	0%	0	18	0%
Zeuzem et al., 2015-3 C-EDGE		(22) GRZ12 + ELB12	0	10	0%	0	10	0%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; NR = not reported; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; q.d. = once daily; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.